Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients

被引:1
|
作者
Kim, Eun Young [1 ]
Lee, Kwan Ho [1 ]
Yun, Ji-Sup [1 ]
Park, Yong Lai [1 ]
Park, Chan Heun [1 ]
Jang, Sung Yoon [2 ]
Ryu, Jai Min [2 ]
Lee, Se Kyung [2 ]
Chae, Byung-Joo [2 ]
Lee, Jeong Eon [2 ]
Kim, Seok Won [2 ]
Nam, Seok Jin [2 ]
Yu, Jong Han [2 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Surg, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Breast Surg,Dept Surg, 81 Irwon Ro, Seoul 06351, South Korea
关键词
Breast neoplasms; Mammography; Microcalcification; Neoadjuvant; Recurrence; PATHOLOGICAL COMPLETE RESPONSE; CARCINOMA IN-SITU; COMPLETE ERADICATION; MICROCALCIFICATIONS; CALCIFICATIONS; TRASTUZUMAB; PERTUZUMAB; GUIDELINE; THERAPY; DCIS;
D O I
10.1186/s12905-024-02973-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Residual microcalcifications after neoadjuvant chemotherapy (NAC) are challenging for deciding extent of surgery and questionable for impact on prognosis. We investigated changes in the extent and patterns of microcalcifications before and after NAC and correlated them with pathologic response. We also compared prognosis of patients depending on presence of residual microcalcifications after NAC. Methods A total of 323 patients with invasive breast carcinoma treated with neoadjuvant chemotherapy at Kangbuk Samsung Hospital and Samsung Medical center from March 2015 to September 2018 were included. Patients were divided into four groups according to pathologic response and residual microcalcifications. Non-pCR(w/mic) group was defined as breast non-pCR with residual microcalcifications. Non-pCR(w/o mic) group was breast non-pCR without residual microcalcifications. pCR(w/mic) group was breast pCR with residual microcalcifications. pCR(w/o mic) group was breast pCR without residual microcalcifications. The first aim of this study is to investigate changes in the extent and patterns of microcalcifications before and after NAC and to correlate them with pathologic response. The second aim is to evaluate oncologic outcomes of residual microcalcifications according to pathologic response after NAC. Results There were no statistical differences in the extent, morphology, and distribution of microcalcifications according to pathologic response and subtype after NAC (all p > 0.05). With a median follow-up time of 71 months, compared to pCR(w/o mic) group, the hazard ratios (95% confidence intervals) for regional recurrence were 5.190 (1.160-23.190) in non-pCR(w/mic) group and 5.970 (1.840-19.380) in non-pCR(w/o mic) group. Compared to pCR(w/o mic) group, the hazard ratios (95% CI) for distant metastasis were 8.520 (2.130-34.090) in non-pCR(w/mic) group, 9.120 (2.850-29.200) in non-pCR(w/o mic) group. Compared to pCR(w/o mic), the hazard ratio (95% CI) for distant metastasis in pCR(w/mic) group was 2.240 (0.230-21.500) without statistical significance (p = 0.486). Conclusions Regardless of residual microcalcifications, patients who achieved pCR showed favorable long term outcome compared to non-pCR group.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Dedicated breast PET for predicting residual disease after breast cancer neoadjuvant chemotherapy
    Sasada, S.
    Kadoya, T.
    Goga, N.
    Emi, A.
    Kajitani, K.
    Masumoto, N.
    Haruta, R.
    Kataoka, T.
    Okada, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [32] Predictive Role of GSTs on the Prognosis of Breast Cancer Patients with Neoadjuvant Chemotherapy
    Bai, Yun-Lu
    Zhou, Bing
    Jing, Xiao-Yue
    Zhang, Bin
    Huo, Xiao-Qing
    Ma, Chao
    He, Jian-Miao
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 5019 - 5022
  • [33] Evaluation of pathologic response and residual tumor cellularity following neoadjuvant chemotherapy predict prognosis in breast cancer patients
    Gentile, Damiano
    Sagona, Andrea
    De Carlo, Camilla
    Fernandes, Bethania
    Grimaldi, Simone Di Maria
    Barbieri, Erika
    Gatzemeier, Wolfgang
    Scardina, Lorenzo
    Biondi, Ersilia
    Jacobs, Flavia
    Vatteroni, Giulia
    Tinterri, Corrado
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [34] Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy
    Peintinger, Florentia
    Sinn, Bruno
    Hatzis, Christos
    Albarracin, Constance
    Downs-Kelly, Erinn
    Morkowski, Jerzy
    Gould, Rebekah
    Symmans, W. Fraser
    [J]. MODERN PATHOLOGY, 2015, 28 (07) : 913 - 920
  • [35] Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients
    Lim, Emerson A.
    Gunther, Jacqueline E.
    Kim, Hyun K.
    Flexman, Molly
    Hibshoosh, Hanina
    Crew, Katherine
    Taback, Bret
    Campbell, Jessica
    Kalinsky, Kevin
    Hielscher, Andreas
    Hershman, Dawn L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (03) : 533 - 540
  • [36] Transcriptomic changes in invasive residual cancer after neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Orozco, Javier
    Manughian-Peter, Ayla
    Gago, Francisco
    Chang, Grace
    Grumley, Janie
    Marzese, Diego
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 23 - 24
  • [37] Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients
    Emerson A. Lim
    Jacqueline E. Gunther
    Hyun K. Kim
    Molly Flexman
    Hanina Hibshoosh
    Katherine Crew
    Bret Taback
    Jessica Campbell
    Kevin Kalinsky
    Andreas Hielscher
    Dawn L. Hershman
    [J]. Breast Cancer Research and Treatment, 2017, 162 : 533 - 540
  • [38] Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
    Symmans, W. Fraser
    Peintinger, Florentia
    Hatzis, Christos
    Rajan, Radhika
    Kuerer, Henry
    Valero, Vicente
    Assad, Lina
    Poniecka, Anna
    Hennessy, Bryan
    Green, Marjorie
    Buzdar, Aman U.
    Singletary, S. Eva
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4414 - 4422
  • [39] Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy
    Gonzalez-Angulo, A. M.
    Liu, S.
    Chen, H.
    Chavez-MacGregor, M.
    Sahin, A.
    Hortobagyi, G. N.
    Mills, G. B.
    Do, K. -A.
    Meric-Bernstam, F.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (04) : 909 - 916
  • [40] Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy.
    Tokunaga, Eriko
    Masuda, Takanobu
    Ijichi, Hideki
    Koga, Chinami
    Tajiri, Wakako
    Tanaka, Junko
    Nakamura, Yoshiaki
    Taguchi, Kenichi
    Okamoto, Masahiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)